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Abstract
Background: Breast cancer is a disease rich in diversity, and it can be categorized into the immunohistochemical
intrinsic subtypes : ER/PR + and HER2-, ER/PR + and HER2+, HER2 type, basal-like and unclassified.
Methods: In this study, in addition to the clinicopathological features potentially associated with the intrinsic
subtypes, protein expression and genetic mutations of key molecules associated with breast cancer prognosis and
treatment sensitivity were analyzed. The distribution of subtypes in the patient population and the differences in
marker distribution across the subtypes were investigated.
Results: The immunohistochemical features of 471 consecutive surgical cases of women with primary breast
cancer, treated in a single institution, were examined. There were 306 patients who were ER/PR + HER2- (65%);
41 who were ER/PR + HER2+ (8.7%); 59 with HER2 type (12.5%); 37 with basal-like (7.9%); and 28 patients whose
breast cancer was unclassified (5.9%). There were no significant differences between the subtypes regarding age,
menopausal status, disease stage, lymphatic invasion, blood vessel invasion and lymph node metastasis. Statistically
significant differences were found for histological type and grade. Regarding protein expression and genetic
mutation, significant differences were found in the distribution within each subtype for six out of 12 molecules
investigated.
Conclusions: This study revealed that subtypes differ not only in their clinical pathological profiles, such as
histological types and histological grades, but also in molecular expression. The molecular expression patterns
observed for each intrinsic subtype may help the selection of an optimal treatment strategy.
Background
Breast cancer is a disease rich in diversity, and it can be
categorized into subtypes with distinct biological features.
Sorlie et al. showed that breast cancer can be divided into
five ‘intrinsic subtypes’ by gene expression analysis using a
DNA microarray [1]. Subsequently, Carey et al. reported
that breast cancers can be divided into the five intrinsic
subtypes by a protein expression analysis of estrogen re-
ceptor (ER), progesterone receptor (PR), human epidermal
growth factor receptor type 2 (HER2), epidermal growth
factor receptor (EGFR) and cytokeratin 5 or 6 (CK5/6),
using immunohistochemistry (IHC) [2]. This IHC-intrinsic
subtyping is now widely used [3-6].
The biological characteristics and the clinical presenta-
tions differ between the five intrinsic subtypes [1-6].
Intrinsic subtypes can be useful as reference data in the
existing treatment selection process. Moreover, the de-
velopment of new treatments for breast cancer may need
to take into consideration the intrinsic subtypes. Distri-
bution data, or prevalence (the proportion of each sub-
type in the patient population), and knowledge of the
clinicopathological features associated with each subtype
are being accumulated regarding intrinsic subtypes [1-6].
However, there have so far been few reports on biomarker
protein expression and genetic mutation profiles for the
intrinsic subtypes, particularly in Japanese populations.
Therefore, in this study, the distribution of key molecules
associated with breast cancer prognosis and treatment
sensitivity was investigated, in addition to subtype distri-
bution and associated clinicopathological characteristics.
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More specifically, the protein expression of phosphatase
and tensin homolog deleted on chromosome 10 (PTEN),
insulin-like growth factor-1 receptor (IGF-1R), B-cell
lymphoma 2 (Bcl-2), c-Kit, hepatocyte growth factor re-
ceptor (c-Met), hypoxia-inducible factor 1-alpha (HIF-
1α), alpha-type platelet-derived growth factor receptor
(PDGFRA), survivin, vascular endothelial growth factor
receptor 2 (VEGFR2), vascular endothelial growth fac-
tor A (VEGF-A), in addition to ER, PR, HER2, EGFR,
CK5/6, and PIK3CA genetic mutation were analyzed.
And the differences in biomarker distribution among
the subtypes were investigated. PTEN loss and expres-
sion of c-Kit, c-Met, HIF-1α, PDGFRA VEGFR2, and
VEGF-A have been reported to be worse prognostic
factors for breast cancer, whereas expression of IGF-1R,
Bcl-2 and survivin are reportedly good prognostic
factors for breast cancer.
Ethnic differences have been reported in the preva-
lence of intrinsic subtypes and associated clinicopatho-
logical features [2], and so it is desirable to accumulate
information on the targeted ethnic group when selecting
or developing treatments. In Japan, there have so far
been only a few reports that have investigated the preva-
lence of intrinsic subtypes. The results of this study are
expected to make a significant contribution to the grow-
ing body of data regarding Japanese patients.
Methods
Patients
Candidates for this investigation comprised 471 con-
secutive surgical cases of women with primary breast
cancer who were treated in the Department of Surgery
II, Tokyo Women’s Medical University throughout July
2004 to November 2007, excluding patients in whom
pre-surgical treatment was performed. In cases of bilat-
eral breast cancer, each tumor was separately set as a
sample, and for cases of multiple breast cancer, only the
main tumor was set as a sample and investigated.
Ethical approval
This study protocol was approved by the Ethical Com-
mittee of Tokyo Women's Medical University. This is an
observational study by using stored samples and existing
medical records. Only investigators in Tokyo Women’s
Medical University have been allowed to access data
with personal information.
Methods
Clinicopathological characteristics (menopausal status,
disease stage, histological type, histological grade, tumor
size, lymphatic invasion, blood vessel invasion, lymph
node metastasis), protein expression and genetic muta-
tion were investigated. The differences in distribution
between each subtype were statistically examined and
analyzed. Key biomarkers in breast cancer prognosis and
treatment sensitivity were selected, and their protein
expression was measured by IHC. Gene mutation in
PIK3CA exons 9 and 20 was detected by PCR amplifica-
tion followed by direct sequencing.
Protein expression analysis
In addition to ER, PR, HER2, EGFR and CK5/6, which
are required for subtyping, 10 other molecules reported
to be predictive for breast cancer prognosis and sensitiv-
ity to treatment were assessed: PTEN, IGF-1R, Bcl-2,
c-Kit, c-Met, HIF-1α, PDGFRA, survivin, VEGFR2 and
VEGR-A. For HER2, fluorescence in situ hybridization
was done when IHC was scored as 2+. CK5/6 IHC was
performed on only the triple negative breast tumors
(ER-,PR- and HER2-). The assay conditions and scoring
criteria of IHC assays are shown in the Table 1.
Intrinsic subtypes were assigned as follows: ER/PR +
HER2- (ER + and/or PR+, and HER2-); ER/PR + HER2+
(ER + and/or PR+, and HER2+); HER2 type (ER-, PR- and
HER2+); basal-like (triple negative; ER-, PR-, HER2-, and
EGFR+ and/or CK5/6+); and unclassified (ER-, PR-,
HER2-, EGFR- and CK5/6).
Mutation analysis
Genomic DNA was extracted from paraffin-embedded
tumor tissue sections using DEXPAT® (Takara Bio Inc.,
Shiga Japan). Genomic DNA was amplified by PCR
using the specific amplifying primers for exons 9 and 20
of PIK3CA. The mRNA sequence for PIK3CA was
obtained from GenBank [GenBank:NM_006218]. Since
exon 20 is relatively large (271 bp), the first and second
halves of the gene were separately amplified with one
overlapping region of 57 base pairs. The purified PCR
products were sequenced using BigDye® Terminator
Cycle Sequencing Kit (Applied Biosystems, Foster City,
CA, USA) and analyzed with an automated capillary ABI
PRISM 3100 genetic analyzer (Applied Biosystems). The
DNA chromatograms were analyzed using the SeqScape®
ver2.5 software (Applied Biosystems) for any single mu-
tations, followed by visual confirmation. All mutations iden-
tified were confirmed by a second analysis by independent
PCR amplification and direct sequencing. Genomic DNA
from corresponding normal tissue was subjected to se-
quence analysis to confirm that the nucleotide substitutions
detected in tumor tissues were somatic rather than germ-
line mutations.
Statistical methods
Analysis of variance, Fisher’s exact probability test and
Cochran-Mantel-Haenszel test were performed to evaluate
the statistical significance of any variation in biomarker
prevalence and clinicopathological features within the sub-
types, using SAS software version 9.1.3. For the statistical
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differences between each group, a P-value under 0.05 was
regarded as statistically significant. Exact odds ratio and
95%CI adjusted by age strata (except for menopausal
status) were estimated by using SAS 9.1.3 Freq procedure.
Results
The clinicopathological features for each intrinsic sub-
type as determined by the expression of ER, PR, HER2,
EGFR and CK5/6 are shown in Table 2. Out of the 471
patients, there were 306 who were ER/PR + HER2-
(65.0%), 41 who were ER/PR + HER2+ (8.7%), 59 of
HER2 type (12.5%), 37 of basal-like (7.9%) and 28 patients
of unclassified (5.9%).
There was no significant difference across the subtypes
in age, menopausal status, disease stage, lymphatic inva-
sion, blood vessel invasion or lymph node metastasis
(Level I to III). Significant differences in the distribution
between the intrinsic subtypes was observed when the
cancer was divided into five histological types, namely
papillotubular carcinoma, solid-tubular carcinoma, scir-
rhous carcinoma, noninvasive carcinoma/Paget's disease,
and others. Scirrhous carcinoma was more frequent in
ER/PR + HER2- and ER/PR + HER2+ cases, at 47% and
46%, respectively. Papillotubular carcinoma, scirrhous
carcinoma and solid-tubular carcinoma occurred at al-
most the same frequency for HER2 type, and the fre-
quency of solid-tubular carcinoma was higher for patients
with basal-like IHC compared to other groups, at 62%.
Moreover, there was a significant difference among the in-
trinsic subtypes in the distribution of three histological
types, namely papillotubular carcinoma, solid-tubular car-
cinoma and scirrhous carcinoma (P <0.01). When tumor
size and histological grades of the 406 cases of invasive
carcinoma, excluding noninvasive carcinoma and Paget’s
disease, were compared among intrinsic subtypes, no sig-
nificant differences were observed in tumor size. Signifi-
cant differences (P <0.01) were observed between the
subtypes for the histological grade (Grade I compared to
Grades II and III combined).
Higher histologic grade (Grade II/III) was strongly
associated with HER2 type (odds ratio (OR) 3.84; 95%
CI 1.80, 7.81) and basal-like type (OR 7.43; 95% CI 2.73,
25.45) compared to the reference ER/PR+ Her2- type
(Figure 1). More specifically, the histological grade of
ER/PR + HER2-, in contrast with HER2 type and basal-
like, was strongly associated with lower histologic grade
(Grade I).
Protein expression and genetic mutation overall and
by each intrinsic subtype are shown in Table 3. Overall,
EGFR was expressed by 16.0% of patients, PTEN expression
was reduced in 50.9% of patients and IGF-1R expression
was 85.9%. Bcl-2 expression (Figure 2a) was 65.0% and c-Kit
expression (Figure 2b) was 7.1%; however, there was no
c-Kit expression observed in patients who were ER/PR +
Table 1 Experimental conditions of immunohistochemistry assays
Antibody (clone) Dilution Source Criteria for positive/negative
ER : Antibody (ID5) ×100 Dako Positive: Stained cells >10%
PR : Antibody (PgR636) ×500 Dako Positive: Stained cells >10%
HER2 (HercepTest) Ready to use Dako HercepTest criteria
EGFR (EGFR pharmDx kit) Ready to use Dako EGFR pharmDx kit criteria
CK5/6 (D5/16 B4) ×100 Dako Positive: Stained cells >10%
PTEN (6H2.1) 1:100 Dako - No staining
+ Decreased staining intensity
++ Equal or increased staining intensity
IGF-1R (C-20) 1:50 Santa Cruz Score 0, 1+, 2+, 3+ using HercepTest criteria
Bcl-2 (124) ×50 Dako Positive: Stained cells >10%
c-Kit (polyclonal; CD117) ×500 Dako Positive: Stained cells >10%
c-Met (C-28, polyclonal) 1:100 IBL Positive: Stained cells >10%
HIF-1α (H1alpha67) ×100 Novus Biologicals Positive: Stained cells >10%
PDGFRA (C20, polyclonal) 1:200 Thermo Positive: Stained cells >10%
Survivin (12C4) ×200 Novus Biologicals Positive: Stained cells >20%
VEGFR2 (polyclonal; Flk-1(A-3)) ×100 Santa Cruz Positive: Stained cells >10%
VEGF-A (VG1) Ready to use Thermo Positive: Stained cells >10%
ER: estrogen receptor, PR: progesterone receptor, HER2: human epidermal growth factor receptor type 2, EGFR: epidermal growth factor receptor,
CK5/6: cytokeratin 5 or 6, PTEN: phosphatase and tensin homolog deleted on chromosome 10, IGF-1R: insulin-like growth factor-1 receptor, Bcl-2: B-cell lymphoma
2, c-Met: hepatocyte growth factor receptor, HIF-1α: hypoxia-inducible factor 1-alpha, PDGFRA: alpha-type platelet-derived growth factor receptor, VEGFR2: vascular
endothelial growth factor receptor 2, VEGF-A: vascular endothelial growth factor A.
NOTE. Dako: Tokyo, Japan. Santa Cruz: Tokyo, Japan. IBL: Gunma, Japan. Novus Biologicals: Littleton, Colorado, USA. Thermo: Waltham, Massachusetts, USA.
Tamaki et al. World Journal of Surgical Oncology 2013, 11:293 Page 3 of 13
http://www.wjso.com/content/11/1/293
Table 2 Clinicopathological features for intrinsic subtypes
All cases ER/PR+,
HER2-
ER/PR+,
HER2+
HER2
type
Basal-
like
Unclassified P
Cases (%) 471 (100) 306 (65.0) 41 (8.7) 59 (12.5) 37 (7.9) 28 (5.9)
Mean age at diagnosis (years) 57.3 ±12.6 57.1 ±12.9 55.2 ±8.7 58.5 ±12.0 57.6 ±13.7 59.9 ±13.8 0.57 (Analysis of variance)
Menopausal status at diagnosis 0.8 (Fisher)
Premenopausal 169 (35.9) 115 (37.6) 15 (36.6) 18 (30.5) 11 (29.7) 10 (35.7)
Postmenopausal 302 (64.1) 191 (62.4) 26 (63.4) 41 (69.5) 26 (70.3) 18 (64.3)
Stage 0.1 (Cochran-Mantel-
Haenszel)
0 57 (12.1) 41 (13.4) 2 (4.9) 8 (13.6) 1 (2.7) 5 (17.9)
I 138 (29.3) 97 (31.7) 16 (39.0) 9 (15.2) 9 (24.3) 7 (25.0)
IIA, IIB 232 (49.3) 139 (45.4) 19 (46.3) 34 (57.6) 24 (64.9) 16 (57.1)
IIIA, IIIB, IIIC 40 (8.5) 27 (8.8) 4 (9.8) 7 (11.9) 2 (5.4) 0 (0)
IV 4 (0.8) 2 (0.7) 0 (0) 1 (1.7) 1 (2.7) 0 (0)
Histological type <0.01 (Fisher)
Papillotubular carcinoma 94 (20.0) 49 (16.0) 13 (31.7) 18 (30.5) 7 (18.9) 7 (28.0)
Solid-tubular carcinoma 83 (17.6) 36 (11.8) 6 (14.6) 14 (23.7) 23 (62.2) 4 (14.3)
Scirrhous carcinoma 194 (41.2) 145 (47.4) 19 (46.4) 18 (30.5) 3 (8.1) 9 (32.1)
Noninvasive carcinoma, Paget’s
disease
65 (13.8) 49 (16.0) 2 (4.9) 8 (13.6) 1 (2.7) 5 (17.9)
Others 35 (7.4) 27 (8.8) 1 (2.4) 1 (1.7) 3 (8.1) 3 (10.7)
Histological type (invasive ductal carcinoma only) <0.01 (Fisher)
Papillotubular carcinoma 94 (25.3) 49 (21.3) 13 (34.2) 18 (36.0) 7 (21.2) 7 (35.0)
Solid-tubular carcinoma 83 (22.4) 36 (15.7) 6 (15.8) 14 (28.0) 23 (69.7) 4 (20.0)
Scirrhous carcinoma 194 (52.3) 145 (63.0) 19 (50.0) 18 (36.0) 3 (9.1) 9 (45.0)
Lymphatic invasion 0.31 (Fisher)
Positive 269 (57.1) 169 (55.2) 27 (65.9) 31 (52.5) 26 (70.3) 16 (57.1)
Negative 202 (42.9) 137 (44.8) 14 (34.1) 28 (47.5) 11 (29.7) 12 (42.9)
Blood vessel invasion 0.19 (Fisher)
Positive 33 (7.0) 18 (5.9) 4 (9.8) 8 (13.6) 1 (2.7) 2 (7.1)
Negative 438 (93.0) 288 (94.1) 37 (90.2) 51 (86.4) 36 (97.3) 26 (92.9)
Lymph node metastases (Level I) 0.62 (Fisher)
Positive 88 (18.7) 59 (19.3) 7 (17.1) 14 (23.7) 5 (13.5) 3 (10.7)
Negative 383 (81.3) 247 (80.7) 34 (82.9) 45 (76.3) 32 (86.5) 25 (89.3)
Lymph node metastases (Level II) 0.97 (Fisher)
Positive 30 (6.4) 19 (6.2) 3 (7.3) 4 (6.8) 2 (5.4) 2 (7.1)
Negative 441 (93.6) 287 (93.8) 38 (92.7) 55 (93.2) 35 (94.6) 26 (92.9)
Lymph node metastases (Level III) 0.56 (Fisher)
Positive 16 (3.4) 11 (3.6) 3 (7.3) 1 (1.7) 1 (2.7) 0 (0)
Negative 455 (96.6) 295 (96.4) 38 (92.7) 58 (98.3) 36 (97.3) 28 (100)
Invasive
carcinoma cases
ER/PR+,
HER2-
ER/PR+,
HER2+
HER2
type
Basal-
like
Unclassified P
Cases (%) 406 (100%) 257 (63.3%) 39 (9.6%) 51 (12.6%) 36 (8.9%) 23 (5.7%)
Tumor size 0.54 (Fisher)
≤ 2.0 cm 272 (67.0) 179 (69.6) 24 (61.5) 32 (62.7) 24 (66.7) 13 (56.5)
>2.0 cm 134 (33.0) 78 (30.4) 15 (38.5) 19 (37.3) 12 (33.3) 10 (43.5)
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HER2+. Overall, c-Met expression was 72.6%, and HIF-1α
expression was 34.1%. The expression of PDGFRA was
86.9%. The expression of survivin was 82.4%, VEGFR2
was 68.1% and VEGF-A was 60.4%. Significant differ-
ences were observed between each subtype for EGFR
positivity, PTEN reduction, Bcl-2 positivity, c-Kit, c-Met
and survivin. Exon 9 of PIK3CA was difficult to measure
with paraffin blocks, so there were only 91 cases of suc-
cessful measurements. Out of those, somatic mutation
was observed in eight cases (8.8%). In exon 20 of PIK3CA,
somatic mutation was observed in 28 (7.8%) out of 357
measurable cases.
Table 2 Clinicopathological features for intrinsic subtypes (Continued)
Histological grade (total score) <0.01 (Fisher)
Grade I 200 (49.3) 148 (57.6) 21 (53.8) 14 (27.4) 5 (13.9) 12 (52.2)
Grade II or III 201 (49.5) 106 (41.2) 18 (46.2) 36 (70.6) 31 (86.1) 10 (43.5)
Unknown 5 (1.2) 3 (1.2) 0 (0) 1 (2.0) 0 (0) 1 (4.3)
0.96(0.45-1.97)
0.73(0.38-1.37)
0.70(0.30-1.54)
0.92(0.37-2.19)
1.34(0.60-2.88)
1.48(0.73-2.92)
1.13(0.48-2.55)
1.54(0.58-4.03)
1.21(0.56-2.56)
3.84(1.80-7.81)
7.43(2.73-25.45)
1.19(0.45-3.18)
1.44(0.68-3.15)
0.92(0.50-1.68)
1.88(0.85-4.48)
1.06(0.44-2.58)
1.71(0.37-5.60)
2.37(0.81-6.04)
0.47(0.01-3.32)
1.20(0.13-5.43)
0.73(0.25-1.92)
1.44(0.68-3.02)
0.61(0.17-1.65)
0.54(0.10-1.91)
0.88(0.15-3.47)
1.18(0.28-3.89)
0.79(0.09-3.57)
1.25(0.13-5.79)
1.38(0.22-5.99)
0.41(0.01-2.89)
0.85(0.02-6.41)
0.00(0.00-3.83)
3.69(0.82-31.04)
0.84(0.35-2.24)
8.51(0.98-278.7)
0.73(0.25-2.74)
0.87(0.40-1.92)
2.57(1.18-6.42)
1.52(0.67-3.93)
1.34(0.47-4.03)
0.01 0.1 1 10 100
Post Menopausal status: ER/PR+HER2+
HER2 type
Basal-like
Unclassified
Tumor size >2.0cm: ER/PR+HER2+
HER2 type
Basal-like
Unclassified
Histologic grade II or III ER/PR+HER2+
HER2 type
Basal-like
Unclassified
Lyphatic invasion positive:
ER/PR+HER2+
HER2 type
Basal-like
Unclassified
Blood vessel invasion positive:
HER2 type
Basal-like
Unclassified
Lymph node meta Level positive:
HER2 type
Basal-like
Unclassified
Lymph node meta Level positive:
HER2 type
Basal-like
Unclassified
Lymph node meta Level positive:
HER2 type
Basal-like
Unclassified
Stage -  :
HER2 type
Basal-like
Unclassified
Stage -  :  ER/PR+HER2+
HER2 type
Basal-like
Unclassified
ER/PR+HER2+
ER/PR+HER2+
ER/PR+HER2+
ER/PR+HER2+
ER/PR+HER2+
Figure 1 Odds ratios (95% confidence interval) of clinicopathological features for intrinsic subtypes (reference: ER/PR + HER2-).
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Table 3 Protein expression and genetic mutation by intrinsic subtypes
All cases ER/PR + HER2- ER/PR + HER2+ HER2 type Basal-like Unclassified P
Cases (%) 471 (100) 306 (65.0) 41 (8.7) 59 (12.5) 37 (7.9) 28 (5.9)
EGFR <0.01
Positive 74 (16.0) 16 (5.4) 5 (12.5) 19 (32.8) 34 (91.9) 0 (0)
Negative 388 (84.0) 283 (94.6) 35 (87.5) 39 (67.2) 3 (8.1) 28(100)
Missing 9 7 1 1
PTEN <0.01
Reduced 234 (50.9) 156 (52.7) 18 (43.9) 16 (27.6) 28 (75.7) 16 (57.1)
Normal 226 (49.1) 140 (47.3) 23 (56.1) 42 (72.4) 9 (24.3) 12 (42.9)
Missing 11 10 1
IGF-1R 0.77
Positive 397 (85.9) 255 (85.6) 36 (87.8) 50 (86.2) 30 (81.1) 26 (92.9)
Negative 65 (14.1) 43 (14.4) 5 (12.2) 8 (13.8) 7 (18.9) 2 (7.1)
Missing 9 8 1
Bcl-2 <0.01
Positive 303 (65.0) 249 (83.0) 27 (67.5) 7 (12.1) 6 (16.2) 14 (50.0)
Negative 160 (35.0) 51 (17.0) 13 (32.5) 51 (87.9) 31 (83.8) 14 (50.0)
Missing 8 6 1 1
c-Kit <0.01
Positive 33 (7.1) 15 (5.0) 0 (0) 7 (12.1) 10 (27.0) 1 (3.6)
Negative 433 (92.9) 287 (95.0) 41 (100) 51 (87.9) 27 (73.0) 27 (96.4)
Missing 5 4 1
c-Met 0.03
Positive 328 (72.6) 203 (69.5) 34 (82.9) 47 (85.5) 28 (75.7) 16 (59.3)
Negative 124 (27.4) 89 (30.5) 7 (17.1) 8 (14.5) 9 (24.3) 11 (40.7)
Missing 19 15 4 1
HIF-1α 0.76
Positive 159 (34.1) 110 (36.4) 12 (29.3) 18 (31.0) 11 (29.7) 8 (28.6)
Negative 307 (65.9) 192 (63.6) 29 (70.7) 40 (69.0) 26 (70.2) 20 (71.4)
Missing 5 4
PDGFRA 0.49
Positive 393 (86.9) 255 (87.6) 34 (85.0) 52 (91.2) 30 (81.1) 22 (81.5)
Negative 59 (13.1) 36 (12.4) 6 (15.0) 5 (8.8) 7 (18.9) 5 (18.5)
Missing 19 15 1 2 1
Survivin 0.02
Positive 383 (82.4) 240 (79.5) 34 (85.0) 56 (96.6) 30 (81.1) 23 (82.1)
Negative 82 (17.6) 62 (20.5) 6 (15.0) 2 (3.4) 7 (18.9) 5 (18.9)
Missing 6 4 1 1
VEGFR2 0.59
Positive 318 (68.1) 206 (68.0) 25 (61.0) 44 (75.9) 25 (67.6) 18 (64.3)
Negative 149 (31.9) 97 (32.0) 16 (39.0) 14 (24.1) 12 (32.4) 10 (35.7)
Missing 4 3 1
VEGF-A 0.14
Positive 279 (60.4) 180 (60.0) 25 (61.0) 42 (72.4) 18 (48.6) 14 (50.0)
Negative 183 (39.6) 118 (40.0) 16 (39.0) 16 (27.6) 19 (51.4) 14 (50.0)
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Figure 3 shows associations between biomarker ex-
pressions and intrinsic subtypes with odds ratios when
ER/PR + HER2- is set as a reference group. EGFR ex-
pression was strongly associated with HER2 type (OR
9.64; 95% CI 3.76, 20.53) and basal-like type (OR 104.55;
95% CI 41.51, 856.77). PTEN reduction was associated
with basal-like type (OR 2.57; 95% CI 1.11, 6.37) and in-
versely associated with HER2 type (OR 0.31; 95% CI
0.16, 0.63). Bcl-2 expression was inversely associated
with all the subtypes including ER/PR + HER2+, HER2
type, basal-like and unclassified types. c-Kit expression
was associated with basal-like type, and c-Met and survi-
vin expressions were associated with HER2 type.
When each biomarker expression was compared be-
tween each subtype, with ER/PR + HER2- as a reference
(Table 4), the expression of Bcl-2 was lower in ER/PR +
HER2+, and expression of c-Kit was not observed. The
PTEN reduction and Bcl-2 expression were lower in
HER2 type, and the expression of EGFR, c-Met and sur-
vivin was significantly higher. The expression of EGFR
and c-Kit and the PTEN reduction were significantly
higher in the basal-like type and expression of Bcl-2 was
significantly lower. The expression of Bcl-2 was signifi-
cantly lower in the unclassified type.
The expression of biomarkers whose expression signifi-
cantly differed between subtypes, was compared with that
of ER, PR, HER2 and EGFR, on which subtyping was
made (Table 5). PTEN reduction showed a significant dif-
ference between HER2 positive and negative groups, and
was significantly higher in the reduced expression group
(P < 0.01). Expression of Bcl-2 was significantly higher in
ER positive group (P < 0.01), PR positive group (P < 0.01),
HER2 negative group (P < 0.01), and EGFR negative group
(P < 0.01), respectively, compared to the referent groups.
c-kit expression was significantly lower in ER positive
group (P < 0.01), PR positive group (p < 0.01), and EGFR
negative group (P < 0.01), respectively, compared to the
referent groups. c-Met expression was positive rate signifi-
cantly higher in HER2 positive group (P < 0.01) and EGFR
positive group (P =0.046). The survivin positive rate
showed significant differences between ER positive and
negative, and HER2 positive and negative groups, and was
Table 3 Protein expression and genetic mutation by intrinsic subtypes (Continued)
Missing 9 8 1
PIK3CA exon 9 0.94
Mutated 8 (8.8) 6 (9.7) 0 (0) 1 (10.0) 0 (0) 1 (14.3)
Wild type 83 (91.2) 56 (90.3) 6 (100) 9 (90.0) 6 (100) 6 (85.7)
Missing 380 45 35 49 31 22
PIK3CA exon 20 0.17
Mutated 28 (7.8) 20 (8.7) 4 (14.3) 1 (2.2) 3 (10.3) 0 (0)
Wild type 329 (92.2) 211 (91.3) 24 (85.7) 44 (97.8) 26 (89.7) 24 (100)
Missing 114 75 13 14 8 4
EGFR: epidermal growth factor receptor, PTEN: phosphatase and tensin homolog deleted on chromosome 10, IGF-1R: insulin-like growth factor-1 receptor,
Bcl-2: B-cell lymphoma 2, c-Met: hepatocyte growth factor receptor, HIF-1α: hypoxia-inducible factor 1-alpha, PDGFRA: alpha-type platelet-derived growth factor
receptor, VEGFR2: vascular endothelial growth factor receptor 2, VEGF-A: vascular endothelial growth factor A.
a
b
Figure 2 Immunohistochemistry. a Bcl-2(B-cell lymphoma 2)
positive x200. b c-Kit positive × 200.
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significantly higher in ER negative group (P =0.03), and
HER2 positive group (P < 0.01).
Discussion
This study describes the distribution of the IHC-intrinsic
tumor subtypes, ER/PR + HER2-, ER/PR + HER2+, HER2
type, basal-like and unclassified, among Japanese patients
with breast cancer. Clinicopathological characteristics of
each intrinsic subtype are also presented. The present
study further provides new evidence of the biomarker ex-
pression profile of each intrinsic subtype, which has
scarcely been examined elsewhere.
Distribution of intrinsic subtypes
Distribution of intrinsic subtypes in this study with the
proportion of ER/PR + HER2- (65.0%), ER/PR + HER2+
(8.7%), HER2 type (12.5%), basal-like (7.9%) and unclas-
sified (5.9%) was not essentially different from those
reported elsewhere, as shown in Table 6 that shows sub-
type distributions in different populations [2,3,6].
ER/PR + HER2- subtype
In our investigation, ER/PR + HER2- had a lower histo-
logical grade, higher Bcl-2 expression and lower EGFR
expression compared to the other subtypes. This profile
may play a role in the better prognosis reported for the
ER/PR + HER2-.
The histological grade of ER/PR + HER2- was the low-
est among the five subtypes, and it was significantly
lower than for the HER2 and basal-like types. Among
biomarkers measured, Bcl-2 expression was significantly
higher in ER/PR + HER2- than the other subtypes,
whereas EGFR expression was as low as 5.4%, which was
significantly lower than HER2 and basal-like types.
EGFR expression was reported to be an independently
worse prognostic factor for breast cancer [7], whereas
2.77(0.69-9.44)
9.64(3.76-20.53)
104.55(41.51-856.77)
0.00(0.00-2.75)
0.75(0.35-1.55)
0.31(0.16-0.63)
2.57(1.11-6.37)
1.31(0.55-3.15)
1.38(0.47-4.90)
1.19(0.50-3.13)
0.62(0.24-1.85)
2.14(0.48-18.76)
0.41(0.19-0.99)
0.02(0.01-0.07)
0.04(0.01-0.12)
0.20(0.08-0.49)
0.00(0.00-2.16)
2.70(0.84-7.48)
7.50(2.60-20.96)
0.73(0.02-5.29)
1.98(0.79-5.54)
2.63(1.14-6.70)
1.43(0.61-3.60)
0.58(0.23-1.44)
0.81(0.35-1.77)
0.76(0.38-1.43)
0.73(0.31-1.64)
0.70(0.26-1.72)
0.87(0.31-2.85)
1.38(0.49-4.74)
0.66(0.26-1.97)
0.60(0.20-2.27)
1.32(0.50-4.20)
7.54(1.74-61.08)
1.25(0.05-3.52)
1.41(0.46-4.91)
0.77(0.37-1.65)
1.51(0.77-3.20)
0.93(0.42-2.21)
0.98(0.40-2.52)
1.02(0.49-2.19)
1.74(0.88-3.43)
0.65(0.31-1.38)
0.71(0.30-1.70)
0.00(0.00-7.12)
0.27(0.01-4.29)
0.00(0.00-57.00)
1.91(0.03-36.99)
3.21(0.62-13.95)
0.23(0.01-1.62)
1.07(0.19-4.15)
0.00(0.00-1.41)
EGFR : ER/PR+HER2+
HER2 type
Basal-like
Unclassified
PTEN reduced : ER/PR+HER2+
HER2 type
Basal-like
Unclassified
IGR-1R :  ER/PR+HER2+
HER2 type
Basal-like
Unclassified
bcl-2 : ER/PR+HER2+
HER2 type
Basal-like
Unclassified
c-kit : ER/PR+HER2+
HER2 type
Basal-like
Unclassified
c-Met : ER/PR+HER2+
HER2 type
Basal-like
Unclassified
HIF-1a :  ER/PR+HER2+
HER2 type
Basal-like
Unclassified
PDGFRA:  ER/PR+HER2+
HER2 type
Basal-like
Unclassified
Suvivin : ER/PR+HER2+
HER2 type
Basal-like
Unclassified
VEGFR2 :  ER/PR+HER2+
HER2 type
Basal-like
Unclassified
VEGF-A :  ER/PR+HER2+
HER2 type
Basal-like
Unclassified
PIK3CA exon9 : ER/PR+HER2+
HER2 type
Basal-like
Unclassified
PIK3CA exon20 : ER/PR+HER2+
HER2 type
Basal-like
Unclassified
Figure 3 Odds ratios (95% confidence interval) of biomarker expressions according to intrinsic subtypes (reference: ER/PR + HER2-).
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Table 5 Expression of ER, PR, HER 2 and EGFR by biomarkers whose expression significantly differed between subtypes
ER P PR P HER2 P EGFR P
Biomarkers Positive
(%)
Negative
(%)
Positive
(%)
Negative
(%)
Positive
(%)
Negative
(%)
Positive
(%)
Negative
(%)
PTEN 0.76 0.10 <0.01 0.80
Reduced 163 (50.3) 71 (52.2) 134 (47.7) 100 (55.9) 34 (34.3) 200 (55.4) 39 (52.7) 195 (50.9)
Normal 161 (49.7) 65 (47.8) 147 (52.3) 79 (44.1) 65 (65.7) 161 (44.6) 35 (47.3) 188 (49.1)
Bcl-2 <0.01 <0.01 <0.01 <0.01
Positive 268 (82.0) 35 (25.7) 238 (83.2) 65 (36.7) 34 (34.7) 269 (73.7) 20 (27.4) 279 (72.5)
Negative 59 (18.0) 101 (74.3) 48 (16.8) 112 (63.3) 64 (65.3) 96 (26.3) 53 (73.4) 106 (27.5)
c-Kit <0.01 <0.01 1.00 <0.01
Positive 15 (4.5) 18 (13.2) 11 (3.8) 22 (12.3) 7 (7.1) 26 (7.1) 16 (21.6) 16 (4.1)
Negative 315 (95.5) 118 (86.8) 276 (96.2) 157 (87.7) 92 (92.9) 341 (92.9) 58 (78.4) 371 (95.9)
c-Met 0.42 0.16 <0.01 0.046
Positive 229 (71.3) 99 (75.6) 194 (70.0) 134 (76.6) 81 (84.4) 247 (69.4) 60 (82.2) 267 (70.8)
Negative 92 (28.7) 32 (24.4) 83 (30.0) 41 (23.4) 15 (15.6) 109 (30.6) 13 (17.8) 110 (29.2)
Survivin 0.03 0.06 <0.01 0.24
Positive 263 (80.0) 120 (88.2) 228 (79.7) 155 (86.6) 90 (91.8) 293 (79.8) 64 (87.7) 314 (81.1)
Negative 66 (20.0) 16 (11.8) 58 (20.3) 24 (13.4) 8 (8.2) 74 (20.2) 9 (12.3) 73 (18.9)
Fisher's exact probability test was used for statistical analysis.
ER: estrogen receptor, PR: progesterone receptor, HER2: human epidermal growth factor receptor type 2, EGFR: epidermal growth factor receptor,
PTEN: phosphatase and tensin homolog deleted on chromosome 10, Bcl-2: B-cell lymphoma 2, c-Met: hepatocyte growth factor receptor.
Table 4 Comparison of molecular profile of each intrinsic subtype
ER/PR + HER2- ER/PR + HER2+ HER2 type Basal-like Unclassified
n OR n OR n OR n OR n OR
EGFR
Positive 16 1.0 (Ref) 5 2.77 (0.69, 9.44) 19 9.64 (3.76, 20.53) 34 104.55 (41.51, 856.77) 0 0.00 (0.00, 2.75)
Negative 283 35 39 3 28
PTEN
Reduced 156 1.0 (Ref) 18 0.75 (0.35, 1.55) 16 0.31(0.16, 0.63) 28 2.57 (1.11, 6.37) 16 1.31 (0.55, 3.15)
Normal 140 23 42 9 12
Bcl-2
Positive 249 1.0 (Ref) 27 0.41 (0.19, 0.99) 7 0.02 (0.01, 0.07) 6 0.04 (0.01, 0.12) 14 0.20 (0.08, 0.49)
Negative 51 13 51 31 14
c-Kit
Positive 15 1.0 (Ref) 0 0.00 (0.00, 2.16) 7 2.70 (0.84, 7.48) 10 7.50 (2.60, 20.96) 1 0.73 (0.02, 5.29)
Negative 287 41 51 27 27
c-Met
Positive 203 1.0 (Ref) 34 1.98 (0.79, 5.54) 47 2.63 (1.14, 6.70) 28 1.43 (0.61, 3.60) 16 0.58 (0.23, 1.44)
Negative 89 7 8 9 11
Survivin
Positive 240 1.0 (Ref) 34 1.32 (0.50, 4.20) 56 7.54 (1.74, 61.08) 30 1.25 (0.05, 3.52) 23 1.41 (0.46, 4.91)
Negative 62 6 2 7 5
Results are odds ratio (OR) adjusted by age and 95% confidence interval.
EGFR: epidermal growth factor receptor, PTEN: phosphatase and tensin homolog deleted on chromosome 10, Bcl-2: B-cell lymphoma 2, c-Met: hepatocyte growth
factor receptor.
Tamaki et al. World Journal of Surgical Oncology 2013, 11:293 Page 9 of 13
http://www.wjso.com/content/11/1/293
Bcl-2 expression is known to be a favorable prognostic
factor for breast cancer.
Bcl-2 expression has been reported to correlate with
ER expression [7], and to be inversely correlated with
EGFR expression, HER2 expression and histological
grade [7,8]. The better prognosis that is seen for Bcl-2-
positive breast cancer had thus been attributed to its higher
prevalence of ER expression; however, Dawson et al. [9]
demonstrated Bcl-2 expression to be associated with a
good prognosis independent of ER expression, by compar-
ing the associations between Bcl-2 expression and the
prognosis of an ER positive group with that of an ER nega-
tive group separately.
ER/PR + HER2+ subtype
There was no significant difference in the clinicopathologi-
cal features between ER/PR + HER2- and ER/PR + HER2+
in this investigation. The prevalence of Bcl-2 expression in
ER/PR + HER2+ was lower than that in ER/PR + HER2-.
Dawson et al. [9] demonstrated both Bcl-2 negativity and
HER2 positivity to be associated with a worse prognosis,
and the group with the profile of Bcl-2 negative combined
with HER2 positive showed the shortest survival. Taken to-
gether, the prognosis of ER/PR + HER2+ is thus expected
to be worse than that of ER/PR + HER2-, and this has, in
fact, been reported [5,6].
HER2 type
When the clinicopathological characteristics of HER2
type were examined, higher histological grade (Grade II/
III compared to Grade I) was found to be significantly
associated with HER2 type compared to ER/PR + HER2-
. Kurebayashi et al. [5] and Shibuta et al. [6] also re-
ported a significant difference between the subtypes of
histological grades and the nuclear grades.
In the current study, HER2-overexpressing tumors had a
higher histologic grade, a higher positive rate of c-Met, sur-
vivin and EGFR, and a lower prevalence of PTEN reduc-
tion and Bcl-2 than ER/PR + HER2-. These differences in
the molecular characteristics between ER/PR + HER2- and
HER2 type may contribute to the reported worse prognosis
of HER2 type in comparison to ER/PR + HER2- [2,4-6].
The HER2 signaling pathway is related to EGFR, PTEN,
IGF-1R, c-Met and PIK3CA. Among these biomarkers,
our data demonstrated the proportion of PTEN reduction
to be significantly lower whereas the expression of EGFR
and c-Met was significantly higher in HER2 type than in
ER/PR + HER2-. However, no significant differences be-
tween subtypes were observed in expression of IGF-1R or
PIK3CA mutation frequency. Moreover, in this investiga-
tion, Bcl-2 expression was significantly lower and the
survivin expression was significantly higher in HER2 type.
The Phosphoinositide 3-kinase-Akt also known as pro-
tein kinase B or PKB pathway is downstream of HER2
and is activated by PIK3CA mutation and PTEN loss
[10,11]. PIK3CA mutation is reported to be observed in
25% to 40% of all breast cancers. In this investigation,
PIK3CA mutation in exon 20 in the HER2 type was
found in only one out of the 45 measurable cases (2.2%).
PTEN reduction was observed in 27.6% of the HER2
type cases, and the proportion was smaller than that
for ER/PR + HER2-. Capodanno et al. [10] and Perez-
Tenorio et al. [12] also reported the proportion of
PTEN reduction to be smaller in the group with HER2
overexpression compared to luminal types.
c-Met is known to be involved in several biological func-
tions, including cell proliferation, cell survival, angiogenesis,
cancer cell invasion and metastasis. c-Met has been re-
ported to be frequently expressed in HER2 positive breast
cancers, and in this investigation also, c-Met positivity was
high in HER2 type (85.5%) and ER/PR + HER2+ type
(82.9%). Regarding sensitivity to treatment, there have been
reports suggesting that c-Met expression may be involved
in resistance to trastuzumab [13], and thus the c-Met
expression status should be considered when selecting the
optimal treatment for HER2 type cases.
The EGFR positive rate of HER2 type was the second
highest after basal-like type among the subtypes. EGFR
positivity is reported to be a worse prognostic factor,
and is also reported to be high in HER2 positive breast
cancer [14-21].
The prevalence of Bcl-2 expression in HER2 type was
significantly lower than that in ER/PR + HER2-. Dawson
et al. [9] demonstrated Bcl-2 positivity to be a favorable
prognostic factor independent of HER2 positivity.
Table 6 Comparison of intrinsic subtypes distribution in different populations
Reference Country All patients (%) ER/PR + HER2- ER/PR + HER2+ HER2 type Basel-like Unclassified
Our research Japan 471 (100) 306 (65.0) 41 (8.7) 59 (12.5) 37 (7.9) 28 (5.9)
Shibuta et al. [6] Japan 4,266 (100) 3,046 (71) 321 (8) 398 (9) 501 (12)
Carey et al. [2] US 496 (100) 255 (51.4) 77 (15.5) 33 (6.7) 100 (20.1) 31 (6.3)
African American 196 (100) 93 (47.4) 25 (12.8) 16 (8.2) 52 (26.5) 10 (5.1)
Non-African American 300 (100) 162 (54) 52 (17.3) 17 (5.7) 48 (16) 21 (7)
Tamimi et al. [3] US 2,249 (100) 1,650 (73) 116 (5) 128 (6) 245 (11) 110 (5)
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The positive rate of survivin was 96.6%. There are
many reports describing frequent expression of survivin
in cancer cells, with a prevalence ranging from 60% to
80% in breast cancers [13,22]. Survivin is an apoptosis-
suppressing factor, and is reported to be an independent
factor for a poor prognosis [22]. In our study, survivin
positive rate was relatively high in the HER2 positive
group, ER negative group and PR negative group
(Table 5). Ryan et al. also reported the survivin positive
rate to be as high as 90% and its expression level was
higher in ER negative, PR negative and HER2 positive
breast cancers [23]. Asanuma et al. [16] also found the
survivin positive rate to be higher in HER2 positive can-
cer and furthermore showed survivin expression to be
more frequent in EGFR positive cancer.
In summary, compared to ER/PR + HER2-, HER2 type
showed a higher histologic grade, higher positive rates of
c-Met, survivin and EGFR, and a lower prevalence of
PTEN reduction and Bcl-2. These differences in the
molecular characteristics between ER/PR + HER2- and
HER2 type may explain the reported worse prognosis of
HER2 type in comparison to ER/PR + HER2- [2,4-6].
Basal-like type
In our investigation, histological grade of basal-like type
was significantly higher than for ER/PR + HER2-, which
was concordant with past reports [2-6]. The distribution of
each histologic type among basal-like type breast tumors
showed the frequency of solid-tubular carcinoma to be the
highest at 62.2%, whereas scirrhous carcinoma was most
prevalent among ER/PR + HER2- and ER/PR+ HER2+.
Nakajima et al. [24] also reported the most prevalent
histologic type in ER/PR + HER2- and ER/PR + HER2+
to be scirrhous carcinoma, while the frequency of solid-
tubular carcinoma was as high as that of scirrhous
carcinoma at 34% in basal-like type [24]. A higher pro-
portion of solid-tubular carcinoma in tumors of a
basal-like subtype is also consistent with results by
Tsuda et al., who found EGFR positivity in solid-
tubular carcinoma to be 17% - much higher than that
in scirrhous carcinoma (6%) and papilla-tubular carcin-
oma (3%) [14]. It must be noted that EGFR expression
was one of the criteria for the basal-like subtype classi-
fication in this study, and 91.9% of basal-like cases were
positive for EGFR.
The prevalence of PTEN reduction in basal-like type
tumors was significantly higher than that for ER/PR +
HER2- in this study. López-Knowles et al. [25] also ob-
served the rate of PTEN reduction to be higher than for
the other subtypes, and Marty et al. [26] reported that
PTEN reduction was more prevalent in basal-like type
compared to HER2 type.
Regarding Bcl-2 expression in basal-like type tumors,
the positive rate was significantly lower than that for
ER/PR + HER2- in this study. c-Kit expression has been
reported to be observed in almost all normal breast tis-
sues, while it is frequently diminished or lost in breast
tumor tissues [27]. The c-Kit positive rate in breast can-
cer was reported as 14% by Nielson et al. [28] and 14.7%
by Charpin et al. [24]. In our study, c-Kit expression was
observed in 7.1% of patients overall. Its positive rate in
basal-like type tumors was 27.0%, which was signifi-
cantly higher than that in ER/PR + HER2-. Our results
showing the c-Kit positive rate to be higher in ER nega-
tive, PR negative and EGFR positive groups (Table 5) are
consistent with the difference in the c-Kit positive rate
between basal-like and ER/PR + HER2-. Tsuda et al. [14]
reported a similar relationship of c-Kit expression with
ER, PR and EGFR expressions. c-Kit expression is also
known to be a worse prognostic factor for breast cancer
[29].
From the above, there is a possibility that the charac-
teristics of basal-like type, specifically its higher histo-
logical grades, higher rate of PTEN reduction, lower rate
of Bcl-2 positivity and higher rate of c-Kit positivity
compared to ER/PR + HER2- type, may together help to
explain why the prognosis of basal-like type is poorer
than that for ER/PR + HER2- [2,4-6]. Moreover, since
PTEN reduction is reported to correlate with Akt activ-
ity [26], the inhibition of Akt activation or suppression
of c-Kit signals could thus become a target for treatment
for basal-like type breast cancer.
Unclassified type
In this study, out of the triple negative (ER-, PR- and
HER2-) cases, EGFR- and CK5/6- cases were considered
to have an unclassified subtype. As reported above, the
histological grade of basal-like tumors was significantly
higher than those of ER/PR + HER2-, however there was
no difference between unclassified and ER/PR + HER2-. A
higher nuclear grade of basal-like triple-negative tumors
compared with non-basal-like triple negative (the unclas-
sified type in our study) was observed by Yamamoto et al.
[30] as well.
The expression of Bcl-2 in the unclassified subtype
was significantly lower compared to ER/PR + HER2-;
however, it was higher than that of basal-like type.
Positive IGF-1R expression was higher in the unclassi-
fied group than in ER/PR + HER2- (OR 2.14; 95% CI
0.48, 18.76) though it was not significant, whereas that
of basal-like type was lower than that for ER/PR +
HER2-. Hartog et al. reported the expression of IGF-1R
to be a worse prognostic factor in triple-negative breast
tumors [31].
A lower expression of Bcl-2 and a higher expression of
IGF-1R in unclassified tumors compared to ER/PR +
HER2- were thus suggested to be partly involved in the
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reported worse prognosis of unclassified type cancer
than ER/PR + HER2- [2,4,5].
Although IGF-1R expression was a worse prognostic
factor in triple-negative breast tumors, it was a favorable
prognostic factor in ER positive breast tumors [31]. IGF-
1R expression thus could be used for accurately selecting
patients who are best indicated to undergo IGF-1R-
targeted therapy.
Conclusion
In this study, we clarified not only that the clinicopatho-
logical profiles, such as histological types and histo-
logical grades, vary between the breast cancer subtypes,
but also that there are differences in the molecular ex-
pression profiles between subtypes. The reported differ-
ences in the prognosis between intrinsic subtypes may
therefore be partly attributable to the differences in their
molecular characteristics. Furthermore, the molecular
characteristics of each subtype can be used as reference
data when developing new treatments for breast cancer
and for selecting patients who are sensitive or resistant
to each therapy.
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